Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct043
Abstract: Background: KEYNOTE-189 is a randomized, placebo-controlled, Phase III study of pembro plus pemetrexed-platinum versus placebo plus pemetrexed-platinum among pts with metastatic nonsquamous NSCLC. At median follow-up of 10.5 months, pts in the pembro-combination arm had… read more here.
Keywords: nonsquamous nsclc; plus pemetrexed; pemetrexed platinum; brain metastases ... See more keywords
Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.999343
Abstract: Objectives The availability of immunotherapies has expanded the options for treating metastatic NSCLC, but information is needed regarding outcomes of immunotherapy for patients treated outside of clinical trials. The aim of this retrospective study was… read more here.
Keywords: oncology; therapy; pembrolizumab combination; metastatic nonsquamous ... See more keywords